Literature DB >> 22815006

[Clinical presentation of tuberculosis in routine practice].

R Dinser1, M Frerix, U Müller-Ladner.   

Abstract

Since the beginning of the biologics era tuberculosis is known to be a potential life-threatening complication during treatment of patients with rheumatic diseases. National and international societies have developed recommendations for tuberculosis screening and treatment of patients at risk for development of tuberculosis. Owing to the relative rareness of overt tuberculosis in patients with rheumatic diseases, the experience of individual rheumatologists with this complication is limited. Therefore, we have analyzed the tuberculosis cases from 2006-2011 in our rheumatology referral center (treating more than 1,500 inpatient and 8,000 outpatient cases every year) to obtain a real-life picture more than 10 years after initiation of the first application of biologics outside of controlled clinical trials. We identified 4 cases that illustrate the difficulties of diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815006     DOI: 10.1007/s00393-012-0991-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  22 in total

1.  Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.

Authors:  Xavier Mariette; Gabriel Baron; Florence Tubach; Frédéric Lioté; Bernard Combe; Corinne Miceli-Richard; René-Marc Flipo; Philippe Goupille; Matthieu Allez; Dominique Salmon; Dominique Emilie; Guislaine Carcelain; Philippe Ravaud
Journal:  Ann Rheum Dis       Date:  2012-01-17       Impact factor: 19.103

2.  CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis.

Authors:  A Merlo; D Saverino; C Tenca; C E Grossi; S Bruno; E Ciccone
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  [Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma].

Authors:  Toyotaka Iguchi; Kenji Yokoyama; Masanori Mitsuishi; Chien-Kang Chen; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Rinsho Ketsueki       Date:  2005-09

4.  Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.

Authors:  J Martin; C Walsh; A Gibbs; T McDonnell; U Fearon; J Keane; M B Codd; J Dodd; D Veale; O Fitzgerald; B Bresnihan
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

5.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

6.  Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.

Authors:  Shuji Murakami; Mistuhiro Takeno; Yohei Kirino; Masayoshi Kobayashi; Reikou Watanabe; Makoto Kudo; Atsushi Ihata; Atsuhisa Ueda; Shigeru Ohno; Yuji Watanuki; Takeshi Kaneko; Yoshiaki Ishigatsubo
Journal:  Tuberculosis (Edinb)       Date:  2009-02-10       Impact factor: 3.131

7.  QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases.

Authors:  F Bartalesi; S Vicidomini; D Goletti; C Fiorelli; G Fiori; D Melchiorre; E Tortoli; A Mantella; M Benucci; E Girardi; M M Cerinic; A Bartoloni
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

8.  Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.

Authors:  B Denis; A Lefort; R M Flipo; F Tubach; M Lemann; P Ravaud; D Salmon; X Mariette; O Lortholary
Journal:  Clin Microbiol Infect       Date:  2007-12-10       Impact factor: 8.067

9.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.

Authors:  U Mack; G B Migliori; M Sester; H L Rieder; S Ehlers; D Goletti; A Bossink; K Magdorf; C Hölscher; B Kampmann; S M Arend; A Detjen; G Bothamley; J P Zellweger; H Milburn; R Diel; P Ravn; F Cobelens; P J Cardona; B Kan; I Solovic; R Duarte; D M Cirillo
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

10.  Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Miguel Angel Descalzo
Journal:  Arthritis Rheum       Date:  2007-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.